Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 36.18 kDa 
• Atom Count: 2,399 
• Modelled Residue Count: 287 
• Deposited Residue Count: 303 
• Unique protein chains: 1

 3RVG

Crystals structure of Jak2 with a 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitor

• PDB DOI:  https://doi.org/10.2210/pdb3RVG/pdb

• Classification: TRANSFERASE/TRANSFERASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2011-05-06 Released: 2012-03-21 
• Deposition Author(s): Lim, J., Taoka, B., Otte, R.D., Spencer, K., Dinsmore, C.J., Altman, M.D., Chan, G., Rosenstein, C., Sharma, S., Su, H.P., Szewczak, A.A., Xu, L., Yin, H., Zugay-Murphy, J., Marshall, C.G., Young, J.R.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.50 Å
• R-Value Free: 0.300 
• R-Value Work: 0.221 
• R-Value Observed: 0.225 

Literature

Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.

Lim, J., Taoka, B., Otte, R.D., Spencer, K., Dinsmore, C.J., Altman, M.D., Chan, G., Rosenstein, C., Sharma, S., Su, H.P., Szewczak, A.A., Xu, L., Yin, H., Zugay-Murphy, J., Marshall, C.G., Young, J.R.

(2011) J Med Chem 54: 7334-7349

• PubMed: 21942426 
• DOI: https://doi.org/10.1021/jm200909u
• Primary Citation of Related Structures:  
  3RVG


• PubMed Abstract: 
  

The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.

---

Organizational Affiliation: 

Department of Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Tyrosine-protein kinase JAK2	A	303	Homo sapiens	Mutation(s): 0  Gene Names: JAK2 EC: 2.7.1.112 (PDB Primary Data), 2.7.10.2 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for O60674 (Homo sapiens) Explore O60674  Go to UniProtKB:  O60674
PHAROS:  O60674

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
17P	B [auth A]	1-(cyclohexylamino)-7-(1-methyl-1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide C22 H24 N6 O NSYNFVRSQTTZAL-UHFFFAOYSA-N

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
PTR	A	L-PEPTIDE LINKING	C9 H12 N O6 P		TYR

Binding Affinity Annotations
ID	Source	Binding Affinity
17P	Binding MOAD:  3RVG	IC50: 5 (nM) from 1 assay(s)
	PDBBind:  3RVG	IC50: 5 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.50 Å
• R-Value Free: 0.300 
• R-Value Work: 0.221 
• R-Value Observed: 0.225 
• Space Group: P 6₅

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 124.433	α = 90
b = 124.433	β = 90
c = 36.734	γ = 120

Software Package:

Software Name	Purpose
PHENIX	refinement
PDB_EXTRACT	data extraction
JDirector	data collection
DENZO	data reduction
SCALEPACK	data scaling
HKL-2000	data scaling
REFMAC	phasing

Structure Validation

Entry History 

Deposition Data

• Released Date: 2012-03-21 
Deposition Author(s): Lim, J., Taoka, B., Otte, R.D., Spencer, K., Dinsmore, C.J., Altman, M.D., Chan, G., Rosenstein, C., Sharma, S., Su, H.P., Szewczak, A.A., Xu, L., Yin, H., Zugay-Murphy, J., Marshall, C.G., Young, J.R.

Revision History  

• Version 1.0: 2012-03-21
  Type: Initial release
  
• Version 1.1: 2017-11-08
  Changes: Refinement description